What changed: Rectal cancer
Every dated change on the records linked to Rectal cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 2
June 2025 · 1
2023 · 2
2022 · 3
- 2022Trial resultOPRAOPRA reported
3-year disease-free survival 76% in both arms; 3-year survival without total mesorectal excision 41% (induction) vs 53% (consolidation).
- 2022MilestoneDostarlimabDostarlimab alone produces complete responses in every mismatch-repair deficient rectal cancer treated
A milestone in how this cancer is treated.
- 2022MilestoneOPRAOPRA: about half of patients keep their rectum after total neoadjuvant therapy
A milestone in how this cancer is treated.
2021 · 2
March 2020 · 1
2020 · 2
2004 · 5
- 2004ApprovalBevacizumabBevacizumab approved in US
First-line metastatic colorectal cancer with 5-FU chemotherapy
- 2004ApprovalCetuximabCetuximab approved in US
EGFR-expressing metastatic colorectal cancer (later restricted to RAS wild-type)
- 2004Trial resultCAO/ARO/AIO-94 (German Rectal Cancer Study)CAO/ARO/AIO-94 (German Rectal Cancer Study) reported
5-year local recurrence 6% (preoperative) vs 13% (postoperative); overall survival unchanged.
- 2004MilestoneCAO/ARO/AIO-94 (German Rectal Cancer Study)CAO/ARO/AIO-94: preoperative chemoradiation halves local recurrence
A milestone in how this cancer is treated.
- 2004MilestoneAngelita Habr-GamaHabr-Gama reports watch and wait after complete clinical response in Sao Paulo
A milestone in how this cancer is treated.